Altogether, these results showed that genes related to RAS/RAF/MAPK and STAT5 oncogenic pro-leukemic signaling were downregulated upon the combination treatment of imatinib and ISRIB, presumably enhancing the targeting of leukemia cells by imatinib. The gene discussed is RAF1; the disease is leukemia.